Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ546MR)

This product GTTS-WQ546MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer, Breast Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ546MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14669MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ7871MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ7642MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ1049MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ1139MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ11571MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ13638MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ9940MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA KB-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW